- Home
- BKYI vs RDHL Comparison
BKYI vs RDHL Comparison
Compare BKYI & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- RDHL
- Stock Information
- Founded
- BKYI 1993
- RDHL 2009
- Country
- BKYI United States
- RDHL Israel
- Employees
- BKYI N/A
- RDHL N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- BKYI Technology
- RDHL Health Care
- Exchange
- BKYI Nasdaq
- RDHL Nasdaq
- Market Cap
- BKYI 4.8M
- RDHL 4.3M
- IPO Year
- BKYI 1997
- RDHL N/A
- Fundamental
- Price
- BKYI $0.81
- RDHL $1.91
- Analyst Decision
- BKYI
- RDHL
- Analyst Count
- BKYI 0
- RDHL 0
- Target Price
- BKYI N/A
- RDHL N/A
- AVG Volume (30 Days)
- BKYI 553.9K
- RDHL 15.6K
- Earning Date
- BKYI 08-13-2025
- RDHL 08-28-2025
- Dividend Yield
- BKYI N/A
- RDHL N/A
- EPS Growth
- BKYI N/A
- RDHL N/A
- EPS
- BKYI N/A
- RDHL N/A
- Revenue
- BKYI $6,355,527.00
- RDHL $8,042,999.00
- Revenue This Year
- BKYI $7.45
- RDHL $381.91
- Revenue Next Year
- BKYI $23.29
- RDHL N/A
- P/E Ratio
- BKYI N/A
- RDHL N/A
- Revenue Growth
- BKYI N/A
- RDHL 23.17
- 52 Week Low
- BKYI $0.52
- RDHL $1.71
- 52 Week High
- BKYI $3.68
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- BKYI 49.56
- RDHL 44.55
- Support Level
- BKYI $0.79
- RDHL $2.00
- Resistance Level
- BKYI $0.86
- RDHL $2.08
- Average True Range (ATR)
- BKYI 0.04
- RDHL 0.10
- MACD
- BKYI -0.00
- RDHL 0.01
- Stochastic Oscillator
- BKYI 49.78
- RDHL 37.05
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.